What is the goal of the Metformin trial for AAAs?

The trial aims to determine if Metformin can slow or prevent the growth of abdominal aortic aneurysms, potentially avoiding the need for high-risk surgery.

Who is participating in the abdominal aortic aneurysm trial?

Over 1,000 patients with small abdominal aortic aneurysms are participating in this large, international drug trial.

Home / Health / Diabetes Drug Trial for Deadly Aneurysms

Diabetes Drug Trial for Deadly Aneurysms

Q: What is Metformin being tested for?

Metformin is being tested as a potential treatment for abdominal aortic aneurysms (AAAs), a dangerous swelling of the aorta.

3 Feb

•

Summary

A common diabetes drug, Metformin, is being tested for abdominal aortic aneurysms.
The trial aims to slow or prevent aneurysm growth, avoiding risky surgery.
Over 1,000 patients will participate in this large, international drug trial.

Diabetes Drug Trial for Deadly Aneurysms

A significant clinical trial is underway to evaluate Metformin, a common medication for type 2 diabetes, as a potential treatment for abdominal aortic aneurysms (AAAs). AAAs are dangerous swellings of the aorta, and their rupture can be fatal.

This extensive research, funded by the British Heart Foundation (BHF), is the largest drug trial for AAA to date. It seeks to recruit 1,000 patients over two years across the UK, Australia, and New Zealand. Participants with small AAAs will receive either Metformin or a placebo.

Researchers hope Metformin can prevent AAA growth by reducing inflammation in the aorta. Currently, individuals with small AAAs can only undergo regular monitoring until the condition requires surgery.